Company overview
SonALAsense develops sonodynamic therapy (SDT), a noninvasive drug-device combination using SONALA-001, an intravenous aminolevulinic acid formulation, with MR-guided focused ultrasound to selectively target and kill cancer cells in tumors like high-grade gliomas and blood cancers. The company is advancing SDT in clinical trials, including for recurrent glioblastoma (NCT05370508) and diffuse intrinsic pontine glioma (DIPG), with FDA Fast Track and Orphan Drug designations. Recent $46 million ARPA-H funding supports SDT development for leukemia and multiple myeloma.
Sonodynamic Therapy is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include sonodynamic therapy, sonala-001, brain cancer treatment, glioblastoma, dipg therapy.
Structured facts
- Website
- https://www.sonalasense.com
- Markets served
- United States & Americas
- Keywords
- sonodynamic therapy, sonala-001, brain cancer treatment, glioblastoma, dipg therapy
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What is SonALAsense's core technology and how does it work?
- SonALAsense's sonodynamic therapy (SDT) combines SONALA-001, a proprietary intravenous drug that accumulates in cancer cells, with MR-guided focused ultrasound. Ultrasound generates light via sonoluminescence to activate a drug metabolite, triggering cell death selectively in tumors.
- What cancers is SonALAsense targeting in clinical trials?
- SonALAsense targets high-grade gliomas including recurrent glioblastoma (NCT05370508), diffuse intrinsic pontine glioma (DIPG) with FDA Fast Track designation, and blood cancers like leukemia and multiple myeloma under $46M ARPA-H funding.
- What regulatory designations has SONALA-001 received?
- SONALA-001 has FDA Orphan Drug Designation for malignant gliomas and Fast Track Designation combined with INSIGHTEC Exablate 4000 for DIPG. SDT is in Phase 1/2 clinical trials showing good tolerability.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
